Amended Report of Foreign Issuer (6-k/a)
July 26 2017 - 10:18AM
Edgar (US Regulatory)
FORM 6-K / A
SECURITIES AND EXCHANGE COMMISSION
Washington D.C. 20549
Report of Foreign Issuer
Pursuant to Rule 13a-16 or 15d-16 of
the Securities Exchange Act of 1934
For
period ending
26 July
2017
GlaxoSmithKline plc
(Name
of registrant)
980 Great West Road, Brentford, Middlesex, TW8 9GS
(Address
of principal executive offices)
Indicate
by check mark whether the registrant files or
will
file annual reports under cover Form 20-F or Form 40-F
Form
20-F x Form 40-F
--
Indicate
by check mark whether the registrant by furnishing the
information
contained in this Form is also thereby furnishing the
information
to the Commission pursuant to Rule 12g3-2(b) under the
Securities
Exchange Act of 1934.
Yes
No x
The
following amendment has been made to the Director/PDMR Shareholding
announcement released on 27 April 2017 in respect of the volume of
notional Ordinary Shares acquired by Mr Urs Rohner (Independent
Non-Executive Director) under the share allocation arrangements
for Independent Non-Executive
Directors for the period of service from 1 January 2017 to 31 March
2017.
Price(s)
and volume(s)
|
Price(s)
|
Volume(s)
|
£15.83
|
454.043
|
All
other details remain unchanged.
The
full amended text is shown below.
GlaxoSmithKline
plc (the '
Company
')
Transaction notification
1.
|
Details of PDMR/person closely associated with them
('PCA')
|
a)
|
Name
|
Philip Hampton
|
b)
|
Position/status
|
Non-Executive Chairman
|
c)
|
Initial
notification/
amendment
|
Initial notification
|
2.
|
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
|
a)
|
Name
|
GlaxoSmithKline plc
|
b)
|
LEI
|
5493000HZTVUYLO1D793
|
3.
|
Details of the transaction(s): section to be repeated for (i) each
type of instrument; (ii) each type of transaction; (iii) each date;
and (iv) each place where transaction(s) has been
conducted
|
a)
|
Description
of the financial instrument
|
Ordinary shares of 25 pence each ('Ordinary Shares')
ISIN:
GB0009252882
|
b)
|
Nature
of the transaction
|
Acquisition of notional Ordinary Shares under the share allocation
arrangements for Independent Non-Executive Directors for the period
of service from 1 January 2017 to 31 March 2017.
|
c)
|
Price(s)
and
volume(s)
|
Price(s)
|
Volume(s)
|
£15.83
|
2,763.740
|
d)
|
Aggregated
information
Aggregated
volume Price
|
n/a (single transaction)
|
e)
|
Date
of the transaction
|
2017-04-26
|
f)
|
Place
of the transaction
|
n/a
|
1.
|
Details of PDMR/person closely associated with them
('PCA')
|
a)
|
Name
|
Professor Sir Roy Anderson
|
b)
|
Position/status
|
Independent Non-Executive Director
|
c)
|
Initial
notification/
amendment
|
Initial notification
|
2.
|
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
|
a)
|
Name
|
GlaxoSmithKline plc
|
b)
|
LEI
|
5493000HZTVUYLO1D793
|
3.
|
Details of the transaction(s): section to be repeated for (i) each
type of instrument; (ii) each type of transaction; (iii) each date;
and (iv) each place where transaction(s) has been
conducted
|
a)
|
Description
of the financial instrument
|
Ordinary shares of 25 pence each ('Ordinary Shares')
ISIN: GB0009252882
|
b)
|
Nature
of the transaction
|
Acquisition of notional Ordinary Shares under the share allocation
arrangements for Independent Non-Executive Directors for the period
of service from 1 January 2017 to 31 March 2017.
|
c)
|
Price(s)
and
volume(s)
|
Price(s)
|
Volume(s)
|
£15.83
|
454.043
|
d)
|
Aggregated
information
Aggregated
volume Price
|
n/a (single transaction)
|
e)
|
Date
of the transaction
|
2017-04-26
|
f)
|
Place
of the transaction
|
n/a
|
1.
|
Details of PDMR/person closely associated with them
('PCA')
|
a)
|
Name
|
Mr Vindi Banga
|
b)
|
Position/status
|
Senior Independent Non-Executive Director
|
c)
|
Initial
notification/
amendment
|
Initial notification
|
2.
|
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
|
a)
|
Name
|
GlaxoSmithKline plc
|
b)
|
LEI
|
5493000HZTVUYLO1D793
|
3.
|
Details of the transaction(s): section to be repeated for (i) each
type of instrument; (ii) each type of transaction; (iii) each date;
and (iv) each place where transaction(s) has been
conducted
|
a)
|
Description
of the financial instrument
|
Ordinary shares of 25 pence each ('Ordinary Shares')
ISIN: GB0009252882
|
b)
|
Nature
of the transaction
|
Acquisition of notional Ordinary Shares under the share allocation
arrangements for Independent Non-Executive Directors for the period
of service from 1 January 2017 to 31 March 2017.
|
c)
|
Price(s)
and
volume(s)
|
Price(s)
|
Volume(s)
|
£15.83
|
1,816.172
|
d)
|
Aggregated
information
Aggregated
volume Price
|
n/a (single transaction)
|
e)
|
Date
of the transaction
|
2017-04-26
|
f)
|
Place
of the transaction
|
n/a
|
1.
|
Details of PDMR/person closely associated with them
('PCA')
|
a)
|
Name
|
Dr Vivienne Cox
|
b)
|
Position/status
|
Independent Non-Executive Director
|
c)
|
Initial
notification/
amendment
|
Initial notification
|
2.
|
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
|
a)
|
Name
|
GlaxoSmithKline plc
|
b)
|
LEI
|
5493000HZTVUYLO1D793
|
3.
|
Details of the transaction(s): section to be repeated for (i) each
type of instrument; (ii) each type of transaction; (iii) each date;
and (iv) each place where transaction(s) has been
conducted
|
a)
|
Description
of the financial instrument
|
Ordinary shares of 25 pence each ('Ordinary Shares')
ISIN: GB0009252882
|
b)
|
Nature
of the transaction
|
Acquisition of notional Ordinary Shares under the share allocation
arrangements for Independent Non-Executive Directors for the period
of service from 1 January 2017 to 31 March 2017.
|
c)
|
Price(s)
and
volume(s)
|
Price(s)
|
Volume(s)
|
£15.83
|
335.597
|
d)
|
Aggregated
information
Aggregated
volume Price
|
n/a (single transaction)
|
e)
|
Date
of the transaction
|
2017-04-26
|
f)
|
Place
of the transaction
|
n/a
|
1.
|
Details of PDMR/person closely associated with them
('PCA')
|
a)
|
Name
|
Ms Lynn Elsenhans
|
b)
|
Position/status
|
Independent Non-Executive Director
|
c)
|
Initial
notification/
amendment
|
Initial notification
|
2.
|
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
|
a)
|
Name
|
GlaxoSmithKline plc
|
b)
|
LEI
|
5493000HZTVUYLO1D793
|
3.
|
Details of the transaction(s): section to be repeated for (i) each
type of instrument; (ii) each type of transaction; (iii) each date;
and (iv) each place where transaction(s) has been
conducted
|
a)
|
Description
of the financial instrument
|
American Depositary Shares ('ADSs')
ISIN: US37733W1053
|
b)
|
Nature
of the transaction
|
Acquisition of notional ADSs under the share allocation
arrangements for Independent Non-Executive Directors for the period
of service from 1 January 2017 to 31 March 2017.
|
c)
|
Price(s)
and
volume(s)
|
Price(s)
|
Volume(s)
|
$41.13
|
1,202.913
|
d)
|
Aggregated
information
Aggregated
volume Price
|
n/a (single transaction)
|
e)
|
Date
of the transaction
|
2017-04-26
|
f)
|
Place
of the transaction
|
n/a
|
1.
|
Details of PDMR/person closely associated with them
('PCA')
|
a)
|
Name
|
Dr Jesse Goodman
|
b)
|
Position/status
|
Independent Non-Executive Director
|
c)
|
Initial
notification/
amendment
|
Initial notification
|
2.
|
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
|
a)
|
Name
|
GlaxoSmithKline plc
|
b)
|
LEI
|
5493000HZTVUYLO1D793
|
3.
|
Details of the transaction(s): section to be repeated for (i) each
type of instrument; (ii) each type of transaction; (iii) each date;
and (iv) each place where transaction(s) has been
conducted
|
a)
|
Description
of the financial instrument
|
American Depositary Shares ('ADSs')
ISIN: US37733W1053
|
b)
|
Nature
of the transaction
|
Dr Jesse Goodman was appointed to the Board with effect from 1
January 2016, as previously announced, and in accordance with the
share allocation arrangements for Independent Non-Executive
Directors, 25% of his fees were retained to be reinvested in
notional ADSs at a date to be mutually agreed.
The accumulated balance of the retained fees has now been
reinvested as disclosed below.
Going forward, notional ADSs of the Company will be allocated on a
quarterly basis.
Acquisition of notional ADSs under the share allocation
arrangements for Independent Non-Executive Directors for the period
of service from 1 January 2016 to 31 March 2017.
|
c)
|
Price(s)
and
volume(s)
|
Price(s)
|
Volume(s)
|
$41.13
|
1,739.846
|
d)
|
Aggregated
information
Aggregated
volume Price
|
n/a (single transaction)
|
e)
|
Date
of the transaction
|
2017-04-26
|
f)
|
Place
of the transaction
|
n/a
|
1.
|
Details of PDMR/person closely associated with them
('PCA')
|
a)
|
Name
|
Ms Judy Lewent
|
b)
|
Position/status
|
Independent Non-Executive Director
|
c)
|
Initial
notification/
amendment
|
Initial notification
|
2.
|
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
|
a)
|
Name
|
GlaxoSmithKline plc
|
b)
|
LEI
|
5493000HZTVUYLO1D793
|
3.
|
Details of the transaction(s): section to be repeated for (i) each
type of instrument; (ii) each type of transaction; (iii) each date;
and (iv) each place where transaction(s) has been
conducted
|
a)
|
Description
of the financial instrument
|
American Depositary Shares ('ADSs')
ISIN: US37733W1053
|
b)
|
Nature
of the transaction
|
Acquisition of notional ADSs under the share allocation
arrangements for Independent Non-Executive Directors for the period
of service from 1 January 2017 to 31 March 2017.
|
c)
|
Price(s)
and
volume(s)
|
Price(s)
|
Volume(s)
|
$41.13
|
449.364
|
d)
|
Aggregated
information
Aggregated
volume Price
|
n/a (single transaction)
|
e)
|
Date
of the transaction
|
2017-04-26
|
f)
|
Place
of the transaction
|
n/a
|
1.
|
Details of PDMR/person closely associated with them
('PCA')
|
a)
|
Name
|
Mr Urs Rohner
|
b)
|
Position/status
|
Independent Non-Executive Director
|
c)
|
Initial
notification/
amendment
|
Amendment
|
2.
|
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
|
a)
|
Name
|
GlaxoSmithKline plc
|
b)
|
LEI
|
5493000HZTVUYLO1D793
|
3.
|
Details of the transaction(s): section to be repeated for (i) each
type of instrument; (ii) each type of transaction; (iii) each date;
and (iv) each place where transaction(s) has been
conducted
|
a)
|
Description
of the financial instrument
|
Ordinary shares of 25 pence each ('Ordinary Shares')
ISIN: GB0009252882
|
b)
|
Nature
of the transaction
|
Acquisition of notional Ordinary Shares under the share allocation
arrangements for Independent Non-Executive Directors for the period
of service from 1 January 2017 to 31 March 2017.
|
c)
|
Price(s)
and
volume(s)
|
Price(s)
|
Volume(s)
|
£15.83
|
454.043
|
d)
|
Aggregated
information
Aggregated
volume Price
|
n/a (single transaction)
|
e)
|
Date
of the transaction
|
2017-04-26
|
f)
|
Place
of the transaction
|
n/a
|
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf
by the undersigned, thereunto duly authorised.
|
GlaxoSmithKline plc
|
|
(Registrant)
|
|
|
Date: July
26, 2017
|
|
|
|
|
By: VICTORIA
WHYTE
--------------------------
|
|
|
|
Victoria Whyte
|
|
Authorised
Signatory for and on
|
|
behalf
of GlaxoSmithKline plc
|
GSK (NYSE:GSK)
Historical Stock Chart
From Aug 2024 to Sep 2024
GSK (NYSE:GSK)
Historical Stock Chart
From Sep 2023 to Sep 2024